Roivant's Sale Of Dermavant To Organon
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion
Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million,
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent ...
The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...
The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...
1don MSN
The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...
The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
GlobalData on MSN1d
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trialAclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
Roflumilast cream 0.15% was well tolerated and significantly improved symptoms in adults and children with mild to moderate atopic dermatitis (AD) in two phase 3 trials. The two phase 3 randomized ...
A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback